NCT07086196View on ClinicalTrials.gov

A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer

CompletedOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Metastatic HR+/HER2- Breast Cancer
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY